Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells

Fig. 2

The combination of venetoclax and ATO disrupts the KG1 and KG1a cell cycles. a, b, Cell cycle analysis by flow cytometry after treatment with control (DMSO 0.1% v/v), venetoclax (200 nM), ATO (3 µM), or the combination of venetoclax (200 nM) and ATO (3 µM) for 48 h. Representative histograms of the cell cycles of the gated live KG1 and KG1a cells after treatment (a) and their summary data (b). Values were obtained from three independent experiments, and horizontal bars indicate mean ± s.d

Back to article page